---
{"dg-publish":true,"permalink":"/USMLE/Reproductive/Selective estrogen receptor modulators/"}
---

# Tamoxifen
---
## Mechanism of action
- Competitive <span style="background:rgba(240, 200, 0, 0.2)">antagonist on the estrogen receptors of the breast</span> → ↓ [[USMLE/Reproductive/Breast cancer\|breast cancer]] cell growth
- <span style="background:rgba(240, 200, 0, 0.2)">Agonist on estrogen receptors in the following tissues</span>:
	- Bone tissue → inhibition of [[USMLE/MSK/Bone remodeling\|osteoclasts]] → ↓ risk of [[USMLE/MSK/Osteoporosis\|osteoporosis]] and fractures
	- Endometrium → ↑ proliferation
	- Myometrium → ↑ proliferation
## Indications
- <span style="background:rgba(240, 200, 0, 0.2)">Premenopausal estrogen receptor-positive [[USMLE/Reproductive/Breast cancer\|breast cancer]]</span>
- Vaginal atrophy (related to [[USMLE/Reproductive/Menopause\|menopause]])
- [[USMLE/Renal/Prostate cancer\|Prostate cancer]]: prevention of [[USMLE/Reproductive/Gynecomastia\|gynecomastia]]
## Side effects
- Hot flashes
- <span style="background:rgba(240, 200, 0, 0.2)">↑ Risk of [[USMLE/Reproductive/Endometrial cancer\|endometrial cancer]]</span>
- <span style="background:rgba(240, 200, 0, 0.2)">↑ Risk of [[USMLE/Reproductive/Uterine leiomyoma#Uterine leiomyosarcoma (uterine sarcoma)\|Uterine leiomyoma#Uterine leiomyosarcoma (uterine sarcoma)]]</span>
- <span style="background:rgba(240, 200, 0, 0.2)">↑ Risk of thromboembolic events (e.g., [[USMLE/Respiratory/Pulmonary embolism\|pulmonary embolism]], DVT)</span>
	- Proposed mechanisms include increased levels of clotting factors (eg, prothrombin; fibrinogen; factor VII, VIII, X) and activated [[USMLE/Blood/Inhibition of hemostasis\|protein C]] resistance.
# Raloxifene
---
## Mechanism of action
- Competitive antagonist on estrogen receptors in the following tissues:
	- Breast → ↓ [[USMLE/Reproductive/Breast cancer\|breast cancer]] cell growth
	- Endometrium and myometrium → ↓ proliferation<span style="background:rgba(240, 200, 0, 0.2)"> (in contrast to tamoxifen)</span>
- Agonist on estrogen receptor in bone tissue → inhibition of [[USMLE/MSK/Bone remodeling\|osteoclasts]]
## Indications
- <span style="background:rgba(240, 200, 0, 0.2)">Prophylaxis of [[USMLE/Reproductive/Breast cancer\|breast cancer]] in high-risk patients</span>
- [[USMLE/MSK/Osteoporosis\|Osteoporosis]] in older patients (if bisphosphonates are contraindicated)
## Side effects
- <span style="background:rgba(240, 200, 0, 0.2)">↓ Risk of [[USMLE/Reproductive/Endometrial cancer\|endometrial cancer]] and uterine sarcoma</span>
# Clomiphene
---
## Mechanism of action
- <span style="background:rgba(240, 200, 0, 0.2)">Blocks hypothalamic estrogen receptors, thereby inhibiting negative feedback and increasing release of FSH and LH to trigger ovulation</span>
## Indications
- Infertility (for ovulation induction)
## Side effects
